A long-acting analog of the pancreatic hormone amylin (co-secreted with insulin from beta cells). Cagrilintide reduces appetite, slows gastric emptying, and suppresses glucagon — complementary to GLP-1 agonism. Combined with semaglutide as CagriSema, the combination achieved up to 25% weight loss in trials.
Cagrilintide is a long-acting acylated analog of amylin, a 37-amino-acid peptide hormone that is co-secreted with insulin from pancreatic beta cells after meals. Amylin's natural functions — slowing gastric emptying, suppressing glucagon, and promoting satiety — complement GLP-1's effects through distinct receptor pathways.
The most exciting development is CagriSema — the fixed-dose combination of cagrilintide + semaglutide in a single weekly injection. In the REDEFINE clinical program, CagriSema achieved approximately 25% weight loss — rivaling surgery and potentially superior to any current single-agent therapy.
Cagrilintide is a long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic β-cells after meals. Amylin complements insulin's glucose-lowering effects by slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety. The only previously approved amylin analog — pramlintide (Symlin) — required injection before every meal due to its short half-life. Cagrilintide's structural modifications enable once-weekly dosing, making it practical for the first time.
The most significant development for cagrilintide is its combination with semaglutide as CagriSema — Novo Nordisk's next-generation obesity treatment. Phase III trials of CagriSema have shown weight loss exceeding 20%, approaching or matching tirzepatide's results. The rationale is compelling: combining amylin receptor agonism (satiety, gastric slowing) with GLP-1 receptor agonism (appetite suppression, insulin secretion) creates a dual-pathway approach through entirely different receptor systems than tirzepatide's GLP-1/GIP mechanism.
If approved, CagriSema would give Novo Nordisk a product to compete directly with Eli Lilly's tirzepatide and potentially retatrutide, maintaining competitive positioning in the rapidly evolving obesity drug market.
Cagrilintide works through amylin receptors in the brainstem, while semaglutide works through GLP-1 receptors in the hypothalamus. Because these are anatomically and pharmacologically distinct satiety pathways, combining them produces additive (possibly synergistic) weight loss. This is the same principle that makes combination drug therapy effective in other diseases — targeting multiple points in a pathway produces greater effects than maxing out a single target.
| Pathway | Effect | Significance |
|---|---|---|
| Amylin receptor agonism | Activates AMY1/AMY3 in area postrema | Distinct satiety pathway from GLP-1 |
| Gastric slowing | Reduces gastric emptying rate | Prolongs satiety and reduces postprandial glucose spikes |
| Glucagon suppression | Reduces inappropriate postprandial glucagon | Complements GLP-1-mediated glucagon suppression |
| Additive with GLP-1 | Different brain targets = additive appetite reduction | CagriSema achieves greater weight loss than either agent alone |
| Acylation | Fatty acid conjugation for albumin binding | Extends half-life for once-weekly injection |
| Study | Design | Findings | Level |
|---|---|---|---|
| REDEFINE 1 | Phase III, n=3,417, 68 weeks | CagriSema 2.4mg: ~25% mean body weight loss. Superior to semaglutide 2.4mg alone (~16%). | Level I |
| REDEFINE 2 | Phase III, T2D | Superior HbA1c reduction and weight loss vs semaglutide alone in T2D patients | Level I |
| Cagrilintide monotherapy | Phase II | Cagrilintide alone produced ~10-11% weight loss at highest dose over 26 weeks | Level II |
| CagriSema vs surgery | Indirect comparison | 25% weight loss approaches outcomes of sleeve gastrectomy (~25-30%) | Indirect |
GI side effects: Nausea, vomiting, and diarrhea are the most common adverse effects, consistent with amylin receptor agonism's effect on gastric motility. When combined with semaglutide (CagriSema), GI side effects may be amplified, though Phase III data suggests the combination is generally well-tolerated with gradual dose escalation.
Hypoglycemia: Amylin analogs can increase hypoglycemia risk when used with insulin. This is less of a concern with cagrilintide alone or in CagriSema for obesity (where patients are not typically on insulin), but is relevant for the Type 2 diabetes indication.
Injection site reactions: Mild injection site reactions reported in clinical trials. No significant systemic safety concerns identified in Phase III data to date.
| Jurisdiction | Status |
|---|---|
| FDA | Not yet approved. NDA submitted 2025 for CagriSema. Decision expected 2025-2026. |
| Novo Nordisk | Developer. Would be next-generation successor to Wegovy. |
| Market impact | If approved, CagriSema could become the most effective obesity medication available |